We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The FDA issued a public health advisory last month warning physicians that use of erythropoiesis-stimulating agents (ESAs) is associated with an increased risk of death and serious life-threatening side effects.